durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Company profile
Ticker
DRRX
Exchange
Website
CEO
James Brown
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943297098
DRRX stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Mar 24
8-K
Other Events
22 Mar 24
8-K
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
4 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
13 Nov 23
8-K
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
7 Nov 23
8-K
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial
7 Sep 23
Transcripts
DRRX
Earnings call transcript
2023 Q4
27 Mar 24
DRRX
Earnings call transcript
2023 Q3
13 Nov 23
DRRX
Earnings call transcript
2023 Q2
9 Aug 23
DRRX
Earnings call transcript
2023 Q1
8 May 23
DRRX
Earnings call transcript
2022 Q4
7 Mar 23
DRRX
Earnings call transcript
2022 Q3
2 Nov 22
DRRX
Earnings call transcript
2022 Q2
6 Aug 22
DRRX
Earnings call transcript
2022 Q1
5 May 22
DRRX
Earnings call transcript
2021 Q4
8 Mar 22
DRRX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
SC 13G
INGALLS & SNYDER LLC
27 Mar 24
SC 13G
ASEN R SCOTT
16 Feb 24
SC 13G/A
Lion Point Capital, LP
14 Feb 24
SC 13G/A
Bleichroeder LP
1 Dec 23
4
Judith J. Robertson
23 Jun 23
4
Gail J Maderis
23 Jun 23
4
PETER S GARCIA
23 Jun 23
4
Gail M Farfel
23 Jun 23
4
Terrence F Blaschke
23 Jun 23
4
MOHAMMAD AZAB
23 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 39.14 mm | 39.14 mm | 39.14 mm | 39.14 mm | 39.14 mm | 39.14 mm |
Cash burn (monthly) | (no burn) | 950.75 k | 3.19 mm | 3.51 mm | 2.49 mm | 2.88 mm |
Cash used (since last report) | n/a | 6.52 mm | 21.85 mm | 24.08 mm | 17.11 mm | 19.72 mm |
Cash remaining | n/a | 32.61 mm | 17.28 mm | 15.05 mm | 22.03 mm | 19.41 mm |
Runway (months of cash) | n/a | 34.3 | 5.4 | 4.3 | 8.8 | 6.8 |
Institutional ownership, Q3 2023
31.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 54 |
Opened positions | 9 |
Closed positions | 12 |
Increased positions | 17 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 19.28 bn |
Total shares | 9.62 mm |
Total puts | 1.21 mm |
Total calls | 565.30 k |
Total put/call ratio | 2.1 |
Largest owners | Shares | Value |
---|---|---|
Bleichroeder | 2.64 mm | $6.57 bn |
Ingalls & Snyder | 1.99 mm | $4.95 mm |
Vanguard | 1.05 mm | $2.60 bn |
CM Management | 525.00 k | $1.31 bn |
Lion Point Capital | 427.46 k | $1.06 bn |
BLK Blackrock | 339.54 k | $845.46 mm |
Dalton Investments | 325.00 k | $809.25 mm |
Renaissance Technologies | 292.67 k | $729.00 k |
Beirne Wealth Consulting Services | 281.31 k | $1.39 bn |
Gagnon Securities | 256.77 k | $639.35 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Jun 23 | Azab Mohammad | Stock Option Common Stock | Grant | Acquire A | No | No | 5.29 | 5,500 | 29.10 k | 5,500 |
21 Jun 23 | Blaschke Terrence F | Stock Option Common Stock | Grant | Acquire A | No | No | 5.29 | 5,500 | 29.10 k | 5,500 |
21 Jun 23 | Gail M Farfel | Stock Option Common Stock | Grant | Acquire A | No | No | 5.29 | 5,500 | 29.10 k | 5,500 |
21 Jun 23 | Garcia Peter S | Stock Option Common Stock | Grant | Acquire A | No | No | 5.29 | 5,500 | 29.10 k | 5,500 |
21 Jun 23 | Gail J Maderis | Stock Option Common Stock | Grant | Acquire A | No | No | 5.29 | 5,500 | 29.10 k | 5,500 |
Press releases
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Mar 24
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
20 Mar 24
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
4 Mar 24
Thinking about buying stock in Vermilion Energy, Staffing 360 Solutions, DURECT, Root Inc, or Ventyx Biosciences?
22 Feb 24
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
7 Feb 24